Bone loss and the aromatase inhibitors.

Br J Cancer · 2005 · PMC2361688 · PMID 16100521

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Surprisingly, bone loss in the placebo group was greater than expected at 1.84 and 1.48% at the spine and hip, respectively, and so there was no significant difference between the two groups, although a clear trend for more rapid bone loss on exemestane was evident.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.